Soleno Therapeutics Investors Invited to Join Securities Fraud Class Action Lawsuit

Opportunity for Soleno Therapeutics Investors

In a recent legal development, shareholders of Soleno Therapeutics, Inc. (SLNO) have been presented with the opportunity to lead a class action lawsuit concerning alleged securities fraud. This lawsuit arises from significant financial losses endured by certain investors following the company’s disclosure of questionable practices related to the clinical trials of its drug, DCCR.

Background of the Lawsuit

The law firm Glancy Prongay Wolke & Rotter LLP has announced the initiation of a class action lawsuit, urging affected investors to step forward. The issue at the heart of this lawsuit revolves around the company's purported failure to adequately disclose safety concerns associated with DCCR during its Phase 3 clinical trials. Specifically, between March 26, 2025, and November 4, 2026, it is claimed that the company misrepresented critical safety data, which may have led to excessive fluid retention among participants in the trials.

Allegations Against Soleno

The allegations paint a troubling picture:
1. Safety Concerns - It is alleged that significant safety issues regarding DCCR were downplayed, misrepresented, or concealed from investors.
2. Market Viability - The drug was found to pose higher safety risks than those disclosed, raising doubts about its commercial viability and increasing the likelihood of serious side effects post-launch.
3. Misleading Statements - Positive portrayals by Soleno executives about the company’s prospects were reportedly unfounded and materially misleading, raising the stakes for investors who relied on these assurances.

These claims are critical, especially for shareholders who may have relied on the company's optimistic outlook regarding DCCR, which was intended to help treat hyperphagia in patients with Prader-Willi syndrome (PWS).

Call to Action for Affected Investors

Investors who believe they may have incurred losses in their Soleno investments are encouraged to participate in this class action lawsuit. The deadline to become a lead plaintiff is set for May 5, 2026. Interested individuals can seek more information by contacting the law firm handling the case. With this legal action, investors may be able to recoup some of their losses and hold the company accountable for its alleged misconduct.

How to Participate

Anyone looking to join the lawsuit or learn more can reach out to Glancy Prongay Wolke & Rotter LLP via their dedicated contact information. It’s important for potential lead plaintiffs to act promptly, as participation is crucial for ensuring that shareholders have a voice in the proceedings against Soleno Therapeutics.

For those who wish to maintain a passive role, they can still remain part of the class action without any immediate actions required.

Conclusion

As the situation unfolds, the outcome of this class action lawsuit may have significant implications not only for the shareholders involved but also for the future practices of Soleno Therapeutics. The case highlights the pressing need for transparency and accountability in public companies, especially those within the biopharmaceutical sector. Investors are reminded to remain vigilant and informed about their investments and the potential risks involved.

For further updates on this developing case, shareholders can check in regularly via the law firm’s website or follow their social media channels.